Page last updated: 2024-10-25

cilostazol and Demyelinating Diseases

cilostazol has been researched along with Demyelinating Diseases in 1 studies

Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.

Research Excerpts

ExcerptRelevanceReference
"Co-treatment with cilostazol prevented paclitaxel-induced dedifferentiation of Schwann cell cultures and demyelination in a mixed culture of Schwann cells and dorsal root ganglia neurons."1.62Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation. ( Imai, S; Iwamitsu, Y; Koyanagi, M; Matsubara, K; Matsumoto, M; Moriya, A; Nakagawa, S; Nakagawa, T; Nakazato, Y; Ogihara, T; Saigo, M; Yonezawa, A, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Koyanagi, M1
Imai, S1
Iwamitsu, Y1
Matsumoto, M1
Saigo, M1
Moriya, A1
Ogihara, T1
Nakazato, Y1
Yonezawa, A1
Nakagawa, S1
Nakagawa, T1
Matsubara, K1

Other Studies

1 other study available for cilostazol and Demyelinating Diseases

ArticleYear
Cilostazol is an effective causal therapy for preventing paclitaxel-induced peripheral neuropathy by suppression of Schwann cell dedifferentiation.
    Neuropharmacology, 2021, 05-01, Volume: 188

    Topics: Animals; Blood Proteins; Breast Neoplasms; Cell Dedifferentiation; Cell Line, Tumor; Cilostazol; Dem

2021